Eloralintide vs Retatrutide
They act on different hormone systems. Eloralintide targets the amylin receptor (satiety and gastric emptying); retatrutide activates three incretin-family receptors at once, adding glucagon-driven energy expenditure. Lilly is also studying eloralintide alongside its incretin agonists, because the amylin and incretin pathways are separate.
Eloralintide
Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist.
BEST STUDIED FOR
Selective amylin-receptor metabolic research
R2 999View product →
Retatrutide
Retatrutide (LY3437943) is a single peptide engineered to activate three receptors at once — GLP-1, GIP and glucagon.
BEST STUDIED FOR
Triple-agonist (GLP-1/GIP/glucagon) metabolic research
FREE GIFTFree GHK-Cu 50 mg with every Retatrutide 30mg vial and free GHK-Cu 100 mg with every Retatrutide 60mg vial, until 15 Oct — one per vial, added automatically at checkout.
Side by side · to buy
Price, purity and dispatch
| Compare | Eloralintide15mg | Retatrutide30 mg · more sizes |
|---|---|---|
| Price | R2,999 | fromR1,749 |
| Cost per mg | R200 / mg | R58.3 / mgLower |
| Purity (Janoshik) | On request | 99.676%HPLC, published |
| Stock | Restocking | Restocking |
| Dispatch | When restocked | When restocked |
| Certificate | Request CoA | View CoA → |
| Literature | 4 papers → | 3 papers → |
| Research focus | Selective amylin-receptor metabolic research | Triple-agonist (GLP-1/GIP/glucagon) metabolic research |
| Notify me | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
RESEARCH PROFILES
0–10 per area, scored from the depth of published research — not a measure of effect.
| Area | Eloralintide | Retatrutide |
|---|---|---|
| Fat Loss & Metabolism | 9 | 10 |
| Appetite Control | 9 | 9 |
| Muscle & Body Composition | 1 | 4 |
| Recovery & Repair | 1 | 3 |
| Skin, Hair & Glow | 1 | 2 |
| Gut & Immune | 2 | 5 |
| Cognition & Focus | 1 | 5 |
| Mood & Calm | 1 | 4 |
| Sleep & Recovery Rhythm | 1 | 5 |
| Longevity & Energy | 4 | 8 |
SIDE BY SIDE
| Eloralintide | Retatrutide | |
|---|---|---|
| The key difference | Amylin pathway only | GLP-1 + GIP + glucagon triple agonist |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist. | Retatrutide (LY3437943) is a single peptide engineered to activate three receptors at once — GLP-1, GIP and glucagon. |
| Status | Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere. | Investigational triple agonist in phase 3 trials; not an approved medicine. |
| Reported safety signals | The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data. | Phase 2 trials reported mainly gastrointestinal adverse events and dose-related heart-rate increases. |
| A key study | Describes eloralintide’s discovery and pharmacology through to clinical proof of concept. (Mol Metab 2025, PMID 41109426) | In a phase-2 randomised trial, participants receiving retatrutide showed dose-dependent reductions in body weight over 48 weeks. (N Engl J Med 2023, PMID 37366315) |
WHEN TO RESEARCH WHICH
Retatrutide for multi-receptor incretin research; eloralintide for isolating the amylin pathway or studying it as an add-on mechanism. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Eloralintide] Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Mol Metab 2025. PMID 41109426
- [Eloralintide] Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes Obes Metab 2026. PMID 41559929
- [Eloralintide] Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet 2025. PMID 41207310
- [Retatrutide] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med 2023. PMID 37366315
- [Retatrutide] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med 2024. PMID 38858523
- [Retatrutide] Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression — NPJ Metab Health Dis 2025. PMID 40094000
FREQUENTLY ASKED
What is the difference between Eloralintide and Retatrutide?
They act on different hormone systems. Eloralintide targets the amylin receptor (satiety and gastric emptying); retatrutide activates three incretin-family receptors at once, adding glucagon-driven energy expenditure. Lilly is also studying eloralintide alongside its incretin agonists, because the amylin and incretin pathways are separate.
What is the regulatory status of Eloralintide and Retatrutide?
Eloralintide: Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere. Retatrutide: Investigational triple agonist in phase 3 trials; not an approved medicine.
What safety signals have been reported?
Eloralintide: The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data. Retatrutide: Phase 2 trials reported mainly gastrointestinal adverse events and dose-related heart-rate increases.
Which studies is this comparison based on?
For Eloralintide: “Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept” (PMID 41109426); “Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept” (PMID 41559929); “Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial” (PMID 41207310). For Retatrutide: “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial” (PMID 37366315); “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial” (PMID 38858523); “Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression” (PMID 40094000).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
Shop this comparison
Supplied for laboratory research only · not for human use